The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma

BACKGROUND: Mepolizumab and omalizumab are treatments for distinct but overlapping severe asthma phenotypes. OBJECTIVE: To assess if patients eligible for both biologics but not optimally controlled with omalizumab experience improved asthma control when switched directly to mepolizumab. METHODS: OS...

Descripción completa

Detalles Bibliográficos
Autores principales: Chapman, Kenneth R., Albers, Frank C., Chipps, Bradley, Muñoz, Xavier, Devouassoux, Gilles, Bergna, Miguel, Galkin, Dmitry, Azmi, Jay, Mouneimne, Dalal, Price, Robert G., Liu, Mark C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790683/
https://www.ncbi.nlm.nih.gov/pubmed/31049972
http://dx.doi.org/10.1111/all.13850

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790683/
https://www.ncbi.nlm.nih.gov/pubmed/31049972
http://dx.doi.org/10.1111/all.13850

Ejemplares similares